市場調查報告書

地中海貧血市場分析,規模,份額,趨勢,預測(2020-2026年):類型,治療級別,最終用途,地區

Thalassemia Market, By Thalassemia Type, By Therapeutic Class, By End Use, and By Geography - Analysis, Size, Share, Trends, & Forecast from 2020-2026

出版商 AnalystView Market Insights 商品編碼 943532
出版日期 內容資訊 英文 188 Pages
商品交期: 2-3個工作天內
價格
地中海貧血市場分析,規模,份額,趨勢,預測(2020-2026年):類型,治療級別,最終用途,地區 Thalassemia Market, By Thalassemia Type, By Therapeutic Class, By End Use, and By Geography - Analysis, Size, Share, Trends, & Forecast from 2020-2026
出版日期: 2020年06月01日內容資訊: 英文 188 Pages
簡介

到2019年,地中海貧血市場規模預計將達到24.8億美元,在2020-2026年預測期內的複合年增長率為9.7%。人口的增長,對高效基因療法的需求不斷增長以及對可用治療方案的認識不斷提高,這是全球地中海貧血市場增長的關鍵驅動力。根據世界衛生組織(WHO)的數據,每10,000例活產中約有4.4例患有地中海貧血。世界上約有5%的人血紅蛋白分子的beta或alpha含量可變。此外,管道藥物開發和新藥開發的激增,再加上研發,是推動市場增長的另一個因素。然而,高成本和缺乏與疾病相關的可行治療方法預計將限制未來的市場增長。同時,預計政府和各大公司在醫療保健方面的投資將在預測期內為整個市場創造有利的增長機會。

本報告對全球地中海貧血市場進行調查和分析,並提供有關市場概況,市場規模和預測,按細分市場進行分析,按地區進行市場分析,競爭情況等方面的系統信息。

第1章地中海貧血市場概述

  • 調查範圍
  • 前提條件和調查方法

第2章執行摘要

  • 市場細分
    • 市場細分:地中海貧血類型
    • 市場細分:按治療類別
    • 市場細分:按最終用途
    • 市場細分:按地區
  • 競爭考察

第3章地中海貧血的主要市場趨勢

  • 促進市場增長的因素
    • 市場增長因素的效果分析
  • 市場增長制約因素
    • 影響市場增長的因素的影響分析
  • 市場機會
  • 未來市場趨勢

第4章地中海貧血行業調查

  • 波特的五力分析
  • 營銷策略分析
  • 增長預測映射
  • 監管框架分析
  • COVID-19影響分析
    • COVID-19之前的影響分析
    • COVID-19之後的影響分析

第5章地中海貧血市場情況

  • 市場份額分析
  • 主要創新者
  • 分析數據:主要製造商
    • 現有公司分析
    • 啟動分析

第6章地中海貧血市場的類型

  • 概述
  • 地中海貧血
  • 地中海貧血

第7章按治療類別劃分的地中海貧血市場

  • 概述
  • 基因療法
  • 鐵螯合劑
  • 輸血
  • 葉酸補充劑

第8章地中海貧血市場的最終用途

  • 概述
  • 醫院
  • 實驗室
  • 研究機構
  • 診所

第9章按地區劃分地中海貧血市場

  • 簡介
    • 按地區劃分的細分市場佔有率分析
  • 北美
    • 概述
    • 北美主要製造商
    • 北美市場規模和國家預測
    • 地中海貧血類型的北美市場規模和預測
    • 北美市場規模和治療類別預測
    • 北美市場規模和最終用途預測
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要製造商
    • 歐洲市場規模和國家預測
    • 地中海貧血類型的歐洲市場規模和預測
    • 歐洲市場規模和治療類別預測
    • 歐洲市場規模和最終用途預測
    • 德國
    • 意大利
    • 英國
    • 法國
    • 其他歐洲
  • 亞太(APAC)
    • 概述
    • 亞太地區主要製造商
    • 亞太地區市場規模和國家預測
    • 地中海貧血類型的亞太市場規模和預測
    • 亞太市場規模和治療級別預測
    • 亞太市場規模和最終用途預測
    • 印度
    • 中國
    • 日本
    • 韓國
    • 亞太地區其他國家
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 拉美市場規模和按國家預測
    • 地中海貧血類型的拉丁美洲市場規模和預測
    • 拉丁美洲市場規模和治療類別預測
    • 拉丁美洲市場規模和最終用途預測
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 中東/非洲
    • 概述
    • 中東和非洲的主要製造商
    • 中東和非洲市場規模及國家預測
    • 地中海貧血症類型的中東和非洲市場規模和預測
    • 中東和非洲市場規模和按治療類別劃分的預測
    • 中東和非洲市場規模及最終用途預測
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國

第10章主要供應商分析

  • Bluebird Bio
  • ApoPharmaInc
  • Sangamo Bioscienc
  • Bellicum Pharmaceuticals
  • Pfizer, Inc.
  • AcceleronPharma/Celgene Corporation
  • Novartis AG
  • KiadisPharma

第11章分析師的全方位視角

第12章附錄

目錄

Title:
Thalassemia Market, By Thalassemia Type (Alpha and Beta), By Therapeutic Class (Iron Chelating Drugs, Blood Transfusion, Gene Therapy, Folic Acid Supplements), By End Use (Hospital, Laboratories, Research Institute, Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) - Analysis, Size, Share, Trends, & Forecast from 2020-2026.

Report Highlight

Thalassemia market was valued at USD 2.48 billion by 2019, growing with 9.7% CAGR during the forecast period, 2020-2026.

Thalassemia is an inherited or genetic blood disorder, which is characterized by the abnormal production of hemoglobin present in the blood cells of the human body. Hemoglobin is the protein that functions to carry oxygen all through the human body, which results in the annihilation of the blood cells leading to anemia.

Market Dynamics

The increasing population, growing demand for enhanced curative gene therapies, and rising awareness regarding available treatment options are the major factors boosting the growth of the global thalassemia market. According to the World Health Organization (WHO), approximately 4.4 every 10,000 live births are affected by thalassemia all across the globe. And, about 5% of the total world population has a variation in the beta or alpha part of the hemoglobin molecule. Furthermore, a surge in the development of pipeline drugs and novel therapies coupled with research & development is another factor propelling the market growth. However, high costs and the lack of viable treatment options associated with the disease are predicted to restrict the market growth in the coming future. On the contrary, the growing investments in healthcare by governments and various key players are expected to create lucrative growth opportunities in the overall market during the forecast period.

Thalassemia Type Takeaway

"Alpha thalassemia segment to witness the fastest growth during the forecast period"

Based on the thalassemia type, the global market is bifurcated into alpha-thalassemia and beta-thalassemia. Of these, the alpha thalassemia segment is estimated to grow at the fastest rate during the forecast period mainly because it is one of the most common autosomal disorders. The growing prevalence of alpha-globin disorders in the U.S. and other western countries is impelling the segmental market growth. In addition, the prevalence of alpha thalassemia is more as compared to the beta-thalassemia, which will fuel the growth of the alpha-thalassemia segment during the forecast period. On the other hand, the beta-thalassemia segment is projected to witness significant growth during the period of forecast. According to the WHO, around 1.5% of the worldwide population is affected by beta-thalassemia.

Therapeutic Class Takeaway

"Blood transfusion segment is anticipated to dominate the industry by 2026"

On the basis of therapeutic class, the overall market for thalassemia is categorized into iron chelating drugs, blood transfusion, folic acid supplements, and gene therapy. The iron-chelating drugs and the gene therapy segment are further sub-categorized into exjade/jadenu (deferasirox) and lentiglobin respectively. Among these, the blood transfusion segment accounted for the largest market share in 2019 and is expected to dominate the industry during the forecast period. This dominance is majorly attributed to the low risk involved in blood transfusion treatment due to careful blood screening. In addition, this treatment has a high success rate compared to other treatments, which makes it most preferable by patients. This will contribute to the segmental market growth in the projected timeframe.

On the other hand, the gene therapy segment is estimated to grow at a considerable rate during the forecast period as it has the potential to change the thalassemia treatment landscape amidst regulatory uncertainties and major clinical development challenges. In addition, scientists are involved in investigating several genetic techniques for the treatment of thalassemia.

Pipeline Products Takeaway

Gene therapy is considered to be the forefront of emerging curative therapies for thalassemia condition, with several genomic molecules under late stage clinical studies. Some of the key players' have already initiative phase III trials for this condition while many are in preclinical evaluation. Recently, a new approach of gene editing for the correction of beta-globin mutation or disruption of the BCL11A gene has been initiated to increase fetal hemoglobin production. This molecule is expected to achieve the preclinical stage soon.

Furthermore, gene correction of autologous hematopoietic stem cells using Lentiviral vectors has been successfully established with a projected launch in the market by 2022. Even though curative possibilities for this disease is expanding, making it accessible to a larger number of patients on a global level remains a challenge.

End Use Takeaway

"Hospital segment to be most lucrative in the forecast period"

Based on end-use, the worldwide thalassemia market is classified into a hospital, research institute, laboratories, and clinics. Among these, the hospital segment accounted for the majority of share in the market in 2009 and is projected to lead the market during the forecast period. This is primarily owing to growth in the number of admissions in hospitals for thalassemia treatment. In addition, the growing prevalence of thalassemia is also likely to drive the segmental market growth. On the other hand, the laboratories segment is expected to hold a significant share in the market throughout the forecast owing to growing awareness amongst people regarding thalassemia treatment.

Regional Takeaway

"North America region to hold a significant market share by 2026"

Depending on the region, the global industry is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America thalassemia market held the highest market share in 2019 and is expected to grow at a significant rate during the period of forecast. This is majorly owing to increasing awareness of thalassemia and the rising incidence of alpha thalassemia in this region.

Moreover, the increased effort by the government in various countries of the North America region to support gene therapy is another responsible for the regional market growth. On the other hand, the Asia Pacific market for thalassemia is expected to grow at the fastest CAGR owing to increasing investments by governments in healthcare infrastructure.

COVID-19 Impact

The worldwide spread of COVID-19 disease has adversely affected the global thalassemia market. Multiple challenges are being faced by the market such as unavailability of blood in blood banks, transfusion facilities, and transportation for the treatment of thalassemia disorders. Moreover, the overall market is likely to recover at a slow rate post the COVID-19 pandemic.

Key Vendor Takeaway

The leading players of the global thalassemia market include Bluebird Bio, ApoPharmaInc, Sangamo Bioscience, Bellicum Pharmaceuticals, Pfizer, Inc., AcceleronPharma / Celgene Corporation, Novartis, KiadisPharma. These players are involved in R&D activities to develop an improved treatment for thalassemia to hold a strong position in the global industry. Companies are involved in developing new products for the disease treatment. For instance, recently, in January 2020, Bluebird Bio launched its first beta thalassemia gene therapy namely, 'Zynteglo' in Germany. A German manufacturer, apceth Biopharma is recruited by the company to produce Zynteglo.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2015 to2018

Base Year - 2019

Estimated Year - 2020

Projected Year - 2026

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Government and Regional Agencies

Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLBOAL THALASSEMIA MARKET KEY PLAYERS

AcceleronPharma / Celgene Corporation

Novartis AG

Bluebird Bio

ApoPharmaInc

Sangamo Bioscience

Bellicum Pharmaceuticals

Pfizer, Inc.

KiadisPharma

GLBOAL THALASSEMIA MARKET, BY THALASSEMIA TYPE

Alpha Thalassemia

Beta Thalassemia

GLBOAL THALASSEMIA MARKET, BY THERAPEUTIC CLASS

Gene Therapy

LentiGlobin

Iron Chelating Drugs

Exjade/Jadenu (deferasirox)

Blood Transfusions

Folic Acid Supplements

GLBOAL THALASSEMIA MARKET, BY END-USE

Research Institutes

Hospital

Laboratories

Clinics

Others

GLOBAL THALASSEMIA MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

TABLE OF CONTENT

1. THALASSEMIA MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Thalassemia Type
    • 2.1.2. Market Snippet by Therapeutic Class
    • 2.1.3. Market Snippet by End Use
    • 2.1.4. Market Snippet by Region
  • 2.2. Competitive Insights

3. THALASSEMIA KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. THALASSEMIA INDUSTRY STUDY

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis
  • 4.5. COVID-19 Impact Analysis
    • 4.5.1. Pre-COVID-19 Impact Analysis
    • 4.5.2. Post-COVID-19 Impact Analysis

5. THALASSEMIA MARKET LANDSCAPE

  • 5.1. Market Share Analysis
  • 5.2. Key Innovators
  • 5.3. Breakdown Data, by Key manufacturer
    • 5.3.1. Established Player Analysis
    • 5.3.2. Emerging Player Analysis

6. THALASSEMIA MARKET - BY THALASSEMIA TYPE

  • 6.1. Overview
    • 6.1.1. Segment Share Analysis, By Thalassemia Type, 2019 & 2026 (%)
  • 6.2. Alpha Thalassemia
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.3. Beta Thalassemia
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

7. THALASSEMIA MARKET - BY THERAPEUTIC CLASS

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Thalassemia Type, 2019 & 2026 (%)
  • 7.2. Gene Therapy
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
      • 7.2.2.1. LentiGlobin
      • 7.2.2.1.1. Overview
      • 7.2.2.1.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.3. Iron Chelating Drugs
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
      • 7.3.2.1. Exjade/Jadenu (deferasirox)
      • 7.3.2.1.1. Overview
      • 7.3.2.1.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.4. Blood Transfusions
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.5. Folic Acid Supplements
    • 7.5.1. Overview
    • 7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

8. THALASSEMIA MARKET - BY END USE

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End Use, 2019 & 2026 (%)
  • 8.2. Hospital
    • 8.2.1. Overview
    • 8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.3. Laboratories
    • 8.3.1. Overview
    • 8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.4. Research Institutes
    • 8.4.1. Overview
    • 8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.5. Clinics
    • 8.5.1. Overview
    • 8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

9. THALASSEMIA MARKET- BY GEOGRAPHY

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Thalassemia Type, 2015 - 2026 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 9.2.6. North America Market Size and Forecast, By End Use, 2015 - 2026 (US$ Million)
    • 9.2.7. U.S.
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.2.8. Canada
      • 9.2.8.1. Overview
      • 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Thalassemia Type, 2015 - 2026 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 9.3.6. Europe Market Size and Forecast, By End Use, 2015 - 2026 (US$ Million)
    • 9.3.7. Germany
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.8. Italy
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.9. United Kingdom
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.10. France
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.11. Rest of Europe
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Thalassemia Type, 2015 - 2026 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 9.4.6. Asia Pacific Market Size and Forecast, By End Use, 2015 - 2026 (US$ Million)
    • 9.4.7. India
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.8. China
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.9. Japan
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.10. South Korea
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.11. Rest of APAC
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Thalassemia Type, 2015 - 2026 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 9.5.6. Latin America Market Size and Forecast, By End Use, 2015 - 2026 (US$ Million)
    • 9.5.7. Brazil
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.5.8. Mexico
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.5.9. Argentina
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Thalassemia Type, 2015 - 2026 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 9.6.6. Middle East and Africa Market Size and Forecast, By End Use, 2015 - 2026 (US$ Million)
    • 9.6.7. Saudi Arabia
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.6.8. United Arab Emirates
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

10. KEY VENDOR ANALYSIS

  • 10.1. Bluebird Bio
    • 10.1.1. Company Snapshot
    • 10.1.2. Financial Performance
    • 10.1.3. Thalassemia Type Benchmarking
    • 10.1.4. Strategic Initiatives
  • 10.2. ApoPharmaInc
  • 10.3. Sangamo Bioscienc
  • 10.4. Bellicum Pharmaceuticals
  • 10.5. Pfizer, Inc.
  • 10.6. AcceleronPharma / Celgene Corporation
  • 10.7. Novartis AG
  • 10.8. KiadisPharma

11. 360 DEGREE ANALYSTVIEW

12. APPENDIX

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Thalassemia market: End Usenapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Thalassemia Type
  • TABLE Global Thalassemia market, by Thalassemia Type 2015-2026 (USD Million)
  • TABLE Thalassemia market: Therapeutic Class Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Class
  • TABLE Global Thalassemia market, by Therapeutic Class 2015-2026 (USD Million)
  • TABLE Thalassemia market: End UseSnapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by End Use
  • TABLE Global Thalassemia market, by End Use2015-2026 (USD Million)
  • TABLE Thalassemia market: Regional Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Thalassemia market, by Region 2015-2026 (USD Million)
  • TABLE North America Thalassemia market, by Country, 2015-2026 (USD Million)
  • TABLE North America Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)
  • TABLE North America Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE North America Thalassemia market, by End Use, 2015-2026 (USD Million)
  • TABLE Europe Thalassemia market, by Country, 2015-2026 (USD Million)
  • TABLE Europe Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)
  • TABLE Europe Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Europe Thalassemia market, by End Use, 2015-2026 (USD Million)
  • TABLE Asia Pacific Thalassemia market, by Country, 2015-2026 (USD Million)
  • TABLE Asia Pacific Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)

TABLEAsia Pacific Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)

  • TABLE Asia Pacific Thalassemia market, by End Use, 2015-2026 (USD Million)
  • TABLE Latin America Thalassemia market, by Country, 2015-2026 (USD Million)
  • TABLE Latin America Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)
  • TABLE Latin America Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Latin America Thalassemia market, by End Use, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Thalassemia market, by Country, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Thalassemia market, by Distribtion Channel, 2015-2026 (USD Million)

List of Figures

  • FIGURE Thalassemia market segmentation
  • FIGURE Market Research Methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2018
  • FIGURE Thalassemia Type segment market share analysis, 2019 & 2026
  • FIGURE Thalassemia Type segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Alpha Thalassemia market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Beta Thalassemia market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Therapeutic Class segment market share analysis, 2019 & 2026
  • FIGURE Therapeutic Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Iron Chelating Drugs market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Exjade/Jadenu (deferasirox) market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Blood Transfusions market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Folic Acid Supplements market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Gene Therapy market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE LentiGlobin market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE End Use segment market share analysis, 2019 & 2026
  • FIGURE End Use segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Hospital market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Laboratories market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Research Institutes market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Clinics market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Regional segment market share analysis, 2019 & 2026
  • FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE North America Thalassemia market share and leading players, 2018
  • FIGURE Europe Thalassemia market share and leading players, 2018
  • FIGURE Asia Pacific Thalassemia market share and leading players, 2018
  • FIGURE Latin America Thalassemia market share and leading players, 2018
  • FIGURE Middle East and Africa Thalassemia market share and leading players, 2018
  • FIGURE North America Thalassemia market share analysis by country, 2018
  • FIGURE U.S. Thalassemia Market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Canada Thalassemia Market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Europe Thalassemia Market share analysis by country, 2018
  • FIGURE Germany Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Spain Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Italy Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE UK Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE FranceThalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of the Europe Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Asia Pacific Thalassemia market share analysis by country, 2018
  • FIGURE India Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE China Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Japan Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE South Korea Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Singapore Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of APACThalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin America Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin AmericaThalassemia market share analysis by country, 2018
  • FIGURE Brazil Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Mexico Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Argentina Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of LATAM Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Thalassemia market share analysis by country, 2018
  • FIGURE Saudi Arabia Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE United Arab Emirates Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)